Your browser doesn't support javascript.
loading
Early drug development in solid tumours: analysis of National Cancer Institute-sponsored phase 1 trials.
Chihara, Dai; Lin, Ruitao; Flowers, Christopher R; Finnigan, Shanda R; Cordes, Lisa M; Fukuda, Yoko; Huang, Erich P; Rubinstein, Larry V; Nastoupil, Loretta J; Ivy, S Percy; Doroshow, James H; Takebe, Naoko.
Affiliation
  • Chihara D; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; Medical Oncology Service, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA. Electronic address: dchihara@mdanderson.org.
  • Lin R; Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Flowers CR; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Finnigan SR; Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
  • Cordes LM; Genitourinary Malignancies Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
  • Fukuda Y; Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
  • Huang EP; Biometric Research Program, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
  • Rubinstein LV; Biometric Research Program, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
  • Nastoupil LJ; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Ivy SP; Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
  • Doroshow JH; Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
  • Takebe N; Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA. Electronic address: takeben@mail.nih.gov.
Lancet ; 400(10351): 512-521, 2022 08 13.
Article in En | MEDLINE | ID: mdl-35964611
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Drug Development / Antineoplastic Agents Type of study: Guideline / Prognostic_studies Limits: Female / Humans / Male Country/Region as subject: America do norte Language: En Journal: Lancet Year: 2022 Document type: Article Country of publication: Reino Unido
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Drug Development / Antineoplastic Agents Type of study: Guideline / Prognostic_studies Limits: Female / Humans / Male Country/Region as subject: America do norte Language: En Journal: Lancet Year: 2022 Document type: Article Country of publication: Reino Unido